Atopic dermatitis : the therapeutic revolution is underway

The therapeutic prospects for patients with moderate to severe atopic dermatitis completely changed in 2017 with the arrival of the first targeted therapy, dupilumab. Achieving important clinical improvement scores are now possible with this monoclonal antibody directed against interleukins 4 and 13...

Full description

Saved in:
Bibliographic Details
Published inRevue médicale de Liège Vol. 77; no. 5-6; p. 377
Main Authors Damsin, Th, Libon, F, Nikkels, A F, Dezfoulian, B
Format Journal Article
LanguageFrench
Published Belgium 01.05.2022
Subjects
Biotherapy
Atopic dermatitis
JAK Inhibitor
IL4 and IL13 antagonists
Online AccessGet more information

Cover

More Information
Summary:The therapeutic prospects for patients with moderate to severe atopic dermatitis completely changed in 2017 with the arrival of the first targeted therapy, dupilumab. Achieving important clinical improvement scores are now possible with this monoclonal antibody directed against interleukins 4 and 13. Since that time, other agents such as tralokinumab arrived on the market, but also the small molecules called «JAK inhibitors» (upadacitinib, baricitinib, etc.). This article provides an inventory of the existing or imminent therapeutic options for atopic dermatitis.
ISSN:0370-629X